Russell E. Tweeddale

United Technologies Corp. engages in the provision of products and services to the building systems and aerospace industries worldwide. It operates through the following business segments: Otis; Carrier; Pratt and Whitney; and Collins Aerospace Systems. The Otis segment designs, manufactures, sells, and installs elevators, escalators, moving walkways, and service. The Carrier segment provides heating, ventilating, air conditioning, and refrigeration solutions. The Pratt and Whitney segment includes aircraft engines for the commercial, military, business jet, and general aviation markets. The Collins Aerospace Systems segment offers technologically advanced aerospace products and aftermarket service solutions for aircraft manufacturers, airlines, regional, business and general aviation markets, military, space and undersea operations. The company was founded in 1934 and is headquartered in Farmington, CT.

Connecticut Innovations, Inc (CI) is venture capital firm founded in 1989. The firm is headquartered in Rocky Hill, Connecticut.

BioRez, Inc. engages in the design and development of resorbable polymer scaffold technology. The firm offers a device that is suited for tendon, ligament, and other soft tissue injuries. The company was founded by Cato T. Laurencin and Joseph W. Reilly in 2008 and is headquartered in New Haven, CT.

EpiEP, Inc. develops heart-related medical devices. It has developed epicardial access system, EpiAccess, which engages a patent protected pressure-guided needle that is designed to alert physicians of needle tip location during epicardial access procedures. The firm specializes on instruments that facilitates an epicardial approach for patients who benefit from minimally invasive procedures on the surface of the heart. The company was founded by Pamela M. Bunes, Jason Tucker-Schwartz, Srijoy Mahapatra and George T. Gillies in December 2008 and is headquartered in New Haven, CT.

LQFX Technology Holdings, Inc. manufactures household and industrial products. It offers lubricants, degreasers, and cleaners. The company was founded in 2010 and is headquartered in Stamford, CT.

Renetx Bio, Inc. operates as a biotechnology company that develops disease modifying therapeutics. It offers Nogo Receptor and Cellular Prion Protein technology. The company was founded by Sylvia McBrinn and Stephen Strittmatter in 2009 and is headquartered in New Haven, CT.

LiveClips LLC develops and delivers video content from live sporting events for any Internet enabled devices. Its advanced technology automates the previously time and labor intensive processes of creating game clips and highlights, enabling broadcasters and rights holders to dramatically increase the efficiency of its sports coverage. The company was founded by Gregg Dearth and Douglas Vunic in 2008 and is headquartered in Wilmington, DE.

Helix Therapeutics is a seed stage company based on technology discovered in the laboratory of Peter Glazer MD/PhD and licensed on a world wide, exclusive basis from Yale University. Targeted DNA modifications can be designed to: correct mutations, leading to restoration of normal function of key gene products, alter levels of gene expression, potentially turning genes on or off, functionally disrupt molecules, such as the CCR5 receptor, which mediates HIV entry into T cells. Through the use of SBIR grants and seed funding, it will advance preclinical projects targeting the human globin gene for applications on sickle cell anemia and beta-thalassemia, the CCR5 receptor for the HIV/AIDS population, and genetic mutations responsible for the liposomal storage disease, Gaucher's. Genetic alteration of stem cells has the potential to dramatically impact the efficacy of stem cell therapy for human disease. Due to the accessibility of HSC without bone marrow transplants, the company is currently focused on blood based genetic diseases. As advances in human stem cell biology are realized, however, it is possible to envision applications in a broad array of human genetic diseases. Moreover, because the DNA modifications introduced to stem cells are stable and heritable; this technology offers the hope of curing certain genetic diseases. Its approach does not rely on viral vectors and corrects the patients own cells, eliminating potential immune reactions. This approach is classified as Cellular Therapy, which provides another level of safety to the patient.